Palivizumab in the prophylaxis of respiratory syncytial virus infection (Q36278040)

13 August 2017

1 reference

title

Palivizumab in the prophylaxis of respiratory syncytial virus infection (English)

1 reference

13 August 2017

Silvia Cardenas

1

1 reference

13 August 2017

Alexander Auais

series ordinal

2

1 reference

13 August 2017

Giovanni Piedimonte

series ordinal

3

1 reference

13 August 2017

1 October 2005

1 reference

Expert Review of Anti-infective Therapy

13 August 2017

1 reference

13 August 2017

3

1 reference

13 August 2017

5

1 reference

13 August 2017

719-726

1 reference

Respiratory syncytial virus and parainfluenza virus

13 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Randomised controlled trial of budesonide for the prevention of post-bronchiolitis wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Rearranged immunoglobulin heavy chain variable region (VH) pseudogene that deletes the second complementarity-determining region

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Effect of respiratory syncytial virus on apnea in weanling rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Deaths among children less than two years of age receiving palivizumab: an analysis of comorbidities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Persistent airway inflammation after resolution of respiratory syncytial virus infection in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.5.719

21 January 2018

Identifiers

DOI

10.1586/14787210.3.5.719

1 reference

release_6rd3fx5mprff5j7u4q7fjuhpdy

13 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6rd3fx5mprff5j7u4q7fjuhpdy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference